Know Cancer

or
forgot password

Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Primary Glioblastoma

Thank you

Trial Information

Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma


Study design

The purpose of the trial is to compare a carbon ion boost to a proton boost delivered to the
macroscopic tumor in combination with combined radiochemotherapy with TMZ in patients with
primary GBM.

The aim of the study is to compare overall survival as a primary endpoint, and progression
free survival, toxicity and safety as secondary endpoints.

Focus of the analysis is to evaluate the change in overall survival and local control by
carbon ion radiotherapy. Therefore, the aim of the trial is to evaluate the improvement in
outcome due to effect of the altered biology of carbon ions on GBM. Chemotherapy with TMZ is
considered standard treatment and is administered continuously as it would be applied in
standard patient care outside any trial.

Trial Design The trial will be performed as a single-center two-armed randomized Phase II
study.

Patients fulfilling the inclusion criteria will be randomized into two arms:

Arm A - Experimental Arm Carbon Ion Radiation Therapy as a Boost to the macroscopic tumor
Total Dose 18 Gy E, 6 fractions, 3 Gy E single dose

Arm B - Standard Arm Proton Radiation Therapy as a Boost to the macroscopic tumor Total Dose
10 Gy E, 5 fractions, 2 Gy E single dose

Standard chemotherapy with TMZ will be continued during the experimental and standard arm in
conventional dosing of 75 mg/m2 per day.


Inclusion Criteria:



- histologically confirmed unifocal, supratentorial primary glioblastoma

- macroscopic tumor after biopsy or subtotal resection

- indication for combined radiochemotherapy with temozolomide

- prior photon irradiation of 48-52 Gy to the T2-hyperintense area, resection cavity,
areas of contrast enhancement adding 2-3cm safety margin in combination with standard
temozolomide

- registration prior to photon RT or within photon RT allowing the beginning of
particle therapy ≤ 4 days after completion of photon irradiation

- beginning of study treatment (proton or carbon ion RT) no later than 12 weeks after
primary diagnosis

- age ≥ 18 years

- Karnofsky Performance Score ≥ 60

- adequate contraception.

- Ability of subject to understand character and individual consequences of the
clinical trial

- Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

- refusal of the patients to take part in the study

- previous radiotherapy of the brain or chemotherapy with DTIC or TMZ other than during
the radiochemotherapy stated in the inclusion criteria

- more than 52 Gy applied via photon-RT prior to particle therapy

- time interval of > 12 weeks after primary diagnosis (neurosurgical intervention) and
beginning of study treatment (proton or carbon ion RT)

- Patients who have not yet recovered from acute toxicities of prior therapies

- Clinically active kidney, liver or cardiac disease

- Known carcinoma < 5 years ago (excluding Carcinoma in situ of the cervix, basal cell
carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment
interfering with study therapy

- Pregnant or lactating women

- Participation in another clinical study or observation period of competing trials,
respectively.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Survival

Outcome Time Frame:

12 months

Safety Issue:

No

Authority:

Germany: Federal Office for Radiation Protection

Study ID:

CLEOPATRA

NCT ID:

NCT01165671

Start Date:

July 2010

Completion Date:

Related Keywords:

  • Primary Glioblastoma
  • Primary Glioblastoma
  • Glioblastoma

Name

Location